Hemodynamic Response
8
0
0
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
38%
3 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Dexmedetomidine in Attenuation of Haemodynamic Response to Laryngoscopy in Controlled Hypertensive Patients
Ischemic Preconditioning in Resistance Exercise in Older Women
Effect of Virtual Reality on Pain, Anxiety, and Vital Signs During Femoral Catheter Removal
Oral Melatonin VS Nebulized Dexmedetomidine Premedication on Attenuation of Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation in Hypertensive Patients
Lidocaine VS Hemodynamic, Metabolic and Hormonal Response
The Impact of Blood Flow Restriction (BFR) on Exercise and Hemodynamic Responses
Comparison of Dexmedetomidine and Fentanyl to Prevent Hemodynamic Response to Skull Pins Application
Use of Lidocaine in Rapid Sequence Induction